NDA 211746 · Glenmark Speclt
Ryaltris
Mometasone Furoate, Olopatadine Hydrochloride · Nasal
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 13, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
251
94 Phase 3, 12 recruiting
FAERS reports
2,035
299 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 21, 2026.
RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients of age 6 years and older. RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. ( 1 )
Mechanism: RYALTRIS contains both olopatadine hydrochloride and mometasone furoate. The mechanisms of action described below for the individual components apply to RYALTRIS. Olopatadine Hydrochloride Olopatadine is a histamine-1 (H1) receptor inhibitor. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans. Mometasone Furoate Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 7, 2026 Supplement 11 · Efficacy LetterLabel
- Jan 13, 2022 Original approval · Type 4 - New Combination LetterLabelReview
1 products under this application
- RYALTRIS · MOMETASONE FUROATE 0.025MG/SPRAY; OLOPATADINE HYDROCHLORIDE 0.665MG/SPRAY · SPRAY, METERED, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00941798 · 2,283 participants · Start Jul 2009 · Primary completion May 2011
Drug: QMF149 Twisthaler®; Mometasone Twisthaler® · For: Asthma
Sites: Birmingham, Alabama; Buena Park, California; Encinitas, California · 146 sites in all
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02554786 · 2,216 participants · Start Dec 29, 2015 · Primary completion Nov 21, 2018
Drug: Indacaterol acetate/Mometasone furoate; Mometasone furoate and 1 more · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 388 sites in all
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)Pivotal-lookingCompleted
ALK-Abelló A/SIndustry
NCT01700192 · 1,482 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: MK-8237 tablets; Placebo tablets and 4 more · For: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03158311 · 1,426 participants · Start Feb 5, 2018 · Primary completion Jul 12, 2019
Drug: QVM149; Salmeterol/fluticasone plus tiotropium · For: Asthma
Sites: Berazategui, Argentina; CABA, Argentina; Caba, Argentina · 163 sites in all
- A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female VolunteersPivotal-lookingCompleted
Mylan Pharmaceuticals IncIndustry
NCT02109185 · 1,307 participants · Start Sep 2013 · Primary completion Oct 2013
Drug: Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.; Nasonex® Nasal Spray, 50 μg/actuation and 2 more · For: Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device delivery system issue705
- product use in unapproved indication612
- drug dose omission by device520
- product use issue431
- drug ineffective198
- device issue160
- wrong technique in device usage process144
- device occlusion134
- epistaxis125
- condition aggravated73
- product tampering71
- device defective64
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2020 | 5 |
| 2022 | 3 |
| 2023 | 258 |
| 2024 | 658 |
| 2025 | 285 |
| 2026 | 825 |
Recalls
1 FDA enforcement reports for this application.
Sep 24, 2024 · Class II · Ongoing
Defective Delivery System: The dip tube is clogged causing the spray not to work.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ryaltris (Olopatadine HCl/Mometasone)
2024 spending
$3.0M
Beneficiaries
4,904
9,849 claims
Per beneficiary
$604
$8.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $15,299 |
| 2023 | $1,046,225 |
| 2024 | $2,962,469 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, et al. · Lancet Respir Med 2025 · Clinical Trial, Phase IV, Comparative Study
- Seborrhoeic dermatitis.
Naldi L · BMJ Clin Evid 2010 · Systematic Review
- Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta-analysis.
Li Y, Xiong J, Zhang Z, et al. · J Evid Based Med 2024 · Systematic Review, Network Meta-Analysis
- The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S, Matsune S, Takeno S, et al. · Laryngoscope 2021 · Clinical Trial, Phase III, Multicenter Study
- Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus.
Chi CC, Kirtschig G, Baldo M, et al. · J Am Acad Dermatol 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The add-on effect of an intranasal antihistamine with an intranasal corticosteroid in Japanese cedar pollinosis.
Haruna T, Kariya S, Higaki T, et al. · Auris Nasus Larynx 2023 · Randomized Controlled Trial
Sponsor: Glenmark Speclt
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.